Skip to content
value.today
DiaMedica Therapeutics Inc. logo

DiaMedica Therapeutics Inc.

DMAC
$469 Mmarket cap on Oct 28, 2026+326.3% since Jan 2024
Compare
World rank
#12,851
Revenue
—
For year ending December-2025
Net income
$-33 M
SEC filing
Employees
35
As of December 31, 2025
SEC filing

DiaMedica Therapeutics Inc. in brief

DiaMedica Therapeutics Inc. is a listed company in the Biotechnology industry, based in Minneapolis, Minnesota, USA. It was founded in 2000. Its market value was $469 M on 28 October 2026, which makes it the 12,851st largest listed company in the world and the 2,572nd largest in the USA on this site. It employs about 35 people and Dietrich John Pauls is its chief executive. Its shares trade under the symbol DMAC (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About DiaMedica Therapeutics Inc.

We are a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from severe ischemic disease with two main clinical programs focused on preeclampsia (PE) / fetal growth restriction (FGR) and acute ischemic stroke (AIS). Our lead candidate DM199 (rinvecalinase alfa), is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (rhKLK1) protein to be clinically studied in patients and has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of AIS. Kallikrein-1 (KLK1), extracted from human urine, is an established therapeutic modality in Asia for the treatment of AIS, and KLK1 produced from pig pancreas, is an established therapeutic modality for the treatment of cardio renal disease, including hypertension, in Asia. We plan to advance DM199 through required clinical trials to create shareholder value by establishing its clinical and commercial potential as a therapy for PE, FGR and AIS. Longer term, we plan to develop DM300, our patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, as a potential therapy for severe acute pancreatitis.

From the company's annual report filed with the US SEC: read the report

DiaMedica Therapeutics Inc. timeline

4 events, 2000–2018
  1. 2000
  2. 🏁
    · approximate
    Founded
  3. 2007
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2014
  6. ✎
    Renamed DiaMedica Therapeutics Inc.
    Formerly DiaMedica Inc..
  7. 2018
  8. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 10 December 2018; shares registered for exchange trading on 3 December 2018.

Events of DiaMedica Therapeutics Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$127 M$253 M$380 M$506 M2020202120222023202420252026

World rank over time

▲ up 8,417 places since 2020
2020-01-01: #21302#21,30220202021-01-01: #15707#15,70720212022-01-07: #23124#23,12420222022-12-25: #26183#26,18320222023-07-30: #20472#20,47220232024-01-05: #20939#20,93920242026-03-08: #7659#7,65920262026-08-01: #13519#13,51920262026-10-14: #13401#13,40120262026-10-28: #12885#12,8852026

Rank in USA: #4,048 (Jan 2020) · #3,270 (Jan 2021) · #4,453 (Jan 2022) · #4,924 (Dec 2022) · #4,001 (Jul 2023) · #3,625 (Jan 2024) · #1,354 (Mar 2026) · #2,732 (Aug 2026) · #2,631 (Oct 2026) · #2,575 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
8.4×
Free cash flow yield
-6.2%
Net margin
—
Operating margin
—
Return on equity
-58.4%
Liabilities / assets
8.6%
R&D / revenue
904.0%
Profit per employee
$-936 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $1M, net income $-6M$1MFY18Fiscal year ending Dec 2019: revenue —, net income $-11M—FY19Fiscal year ending Dec 2020: revenue —, net income $-12M—FY20Fiscal year ending Dec 2021: revenue —, net income $-14M—FY21Fiscal year ending Dec 2022: revenue —, net income $-14M—FY22Fiscal year ending Dec 2023: revenue —, net income $-19M—FY23Fiscal year ending Dec 2024: revenue —, net income $-24M—FY24Fiscal year ending Dec 2025: revenue —, net income $-33M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-34M$-33M—
Dec 2024——$-27M$-24M—
Dec 2023——$-21M$-19M—
Dec 2022——$-14M$-14M—
Dec 2021——$-14M$-14M—
Dec 2020——$-13M$-12M—
Dec 2019——$-12M$-11M—
Dec 2018$1M—$-7M$-6M-1146.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-29M$0M$-29M——
Dec 2024$-22M$0M$-22M——
Dec 2023$-19M$0M$-19M——
Dec 2022$-12M$0M$-12M——
Dec 2021$-12M$0M$-12M$-0.65—
Dec 2020$-9M$0M$-9M$-0.78—
Dec 2019$-9M$0M$-9M$-0.89—
Dec 2018$-6M$0M$-6M$-0.74—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-8M—Dec ’24Three months to Mar 2025: revenue —, net income $-8M—Mar ’25Three months to Jun 2025: revenue —, net income $-8M—Jun ’25Three months to Sep 2025: revenue —, net income $-9M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-9M—Dec ’25Three months to Mar 2026: revenue —, net income $-10M—Mar ’26Three months to Jun 2026: revenue —, net income $-10M—Jun ’26Three months to Sep 2026: revenue —, net income $-11M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-11M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of DiaMedica Therapeutics Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-34 M
Net income
$-33 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$61 M
Total liabilities
$5 M
Total equity
$56 M

As of December-2025

Top 97 institutional investors in DiaMedica Therapeutics Inc.#

As of Sep 30, 2026
97 institutions held 12.8 M shares (about 23.8% of the shares outstanding) on Sep 30, 2026. The ten largest hold 18.0%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in DiaMedica Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Cooperman Leon G3,450,0000 (0.00%)6.39%$29 MNov 16, 2026
2BlackRock, Inc.2,209,329-42,956 (-1.91%)4.09%$18 MNov 13, 2026
3Geode Capital Management, LLC893,827-288 (-0.03%)1.66%$7 MNov 6, 2026
4Millennium Management LLC831,081-14,228 (-1.68%)1.54%$7 MNov 16, 2026
5State Street Corp659,728+12,985 (+2.01%)1.22%$5 MNov 12, 2026
6Bleichroeder LP382,3170 (0.00%)0.71%$3 MNov 13, 2026
7Vanguard Capital Management LLC360,556+5,033 (+1.42%)0.67%$3 MNov 13, 2026
8Osaic Holdings, Inc.330,095-8,012 (-2.37%)0.61%$3 MNov 12, 2026
9Northern Trust Corp326,296-1,222 (-0.37%)0.60%$3 MNov 16, 2026
10Vanguard Portfolio Management LLC256,510+4,839 (+1.92%)0.48%$2 MNov 13, 2026
11LPL Financial LLC235,850+2,350 (+1.01%)0.44%$2 MNov 6, 2026
12Vanguard Fiduciary Trust Co206,457-981 (-0.47%)0.38%$2 MNov 13, 2026
13Goldman Sachs Group Inc187,465+19,399 (+11.54%)0.35%$2 MNov 16, 2026
14Citadel Advisors LLC184,950+39,080 (+26.79%)0.34%$2 MNov 16, 2026
15Trexquant Investment LP163,372+78,724 (+93.00%)0.30%$1 MNov 16, 2026
16Bank of New York Mellon Corp117,8200 (0.00%)0.22%$1 MNov 5, 2026
17Hurricane Capital Advisors LLC111,582+44,110 (+65.38%)0.21%$1 MNov 16, 2026
18Cobalt Capital Management, Inc.104,872+14,872 (+16.52%)0.19%$1 MNov 13, 2026
19Charles Schwab Investment Management Inc101,805+5,114 (+5.29%)0.19%$1 MNov 16, 2026
20Members Wealth LLC101,3820 (0.00%)0.19%$1 MOct 20, 2026
21Gsa Capital Partners LLP97,026+24,461 (+33.71%)0.18%$1 MNov 16, 2026
22XTX Topco Ltd82,199+67,103 (+444.51%)0.15%$1 MNov 16, 2026
23Diametric Capital, LP80,914+4,293 (+5.60%)0.15%$1 MNov 16, 2026
24Magnolia Capital Advisors LLC77,4050 (0.00%)0.14%$1 MNov 16, 2026
25Bank Of America Corp /de/77,373+19,661 (+34.07%)0.14%$1 MNov 16, 2026
Show all 97: investors 26 to 97
Institutional investors 26 to 97 in DiaMedica Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Morgan Stanley71,093+24,219 (+51.67%)0.13%$1 MNov 13, 2026
27Squarepoint Ops LLC70,606-74,641 (-51.39%)0.13%$1 MNov 9, 2026
28Blue Trust, Inc.69,1220 (0.00%)0.13%$1 MOct 15, 2026
29AWM Investment Company, Inc.65,097+29,097 (+80.83%)0.12%$1 MNov 13, 2026
30Private Capital Management, LLC60,000+10,000 (+20.00%)0.11%$0 MNov 16, 2026
31Corient IA LP60,000+25,000 (+71.43%)0.11%$0 MNov 16, 2026
32Nuveen, LLC56,121+7,772 (+16.07%)0.10%$0 MNov 10, 2026
33Meridian Wealth Management, LLC43,6000 (0.00%)0.08%$0 MNov 5, 2026
34Ballentine Partners, LLC40,621-391 (-0.95%)0.08%$0 MNov 13, 2026
35Tocqueville Asset Management L.P.40,200New0.07%$0 MNov 13, 2026
36Catalyst Financial Partners LLC38,4570 (0.00%)0.07%$0 MNov 6, 2026
37Cetera Investment Advisers33,840New0.06%$0 MNov 13, 2026
38Creative Planning32,381+8,241 (+34.14%)0.06%$0 MNov 2, 2026
39Deutsche Bank AG\31,859-4,464 (-12.29%)0.06%$0 MNov 6, 2026
40Price T Rowe Associates Inc /MD/30,4920 (0.00%)0.06%$0 MNov 16, 2026
41Rhumbline Advisers30,067-1,393 (-4.43%)0.06%$0 MNov 10, 2026
42HSBC Holdings PLC28,847-5,377 (-15.71%)0.05%$0 MNov 16, 2026
43Susquehanna International Group, LLP24,254New0.04%$0 MNov 16, 2026
44AQR Capital Management LLC23,584+12,457 (+111.95%)0.04%$0 MNov 16, 2026
45Invesco Ltd.19,239-465 (-2.36%)0.04%$0 MNov 12, 2026
46Barclays PLC18,353+5,208 (+39.62%)0.03%$0 MNov 6, 2026
47Jpmorgan Chase & Co18,153+2,960 (+19.48%)0.03%$0 MNov 12, 2026
48MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.17,491+616 (+3.65%)0.03%$0 MNov 16, 2026
49HighTower Advisors, LLC17,000-75 (-0.44%)0.03%$0 MNov 10, 2026
50FMR LLC16,471+7,568 (+85.01%)0.03%$0 MNov 10, 2026
51Cornerstone Wealth Management, LLC16,2500 (0.00%)0.03%$0 MNov 4, 2026
52Raymond James Financial Inc15,7910 (0.00%)0.03%$0 MNov 12, 2026
53Bank Of Montreal /can/15,562-39,382 (-71.68%)0.03%$0 MNov 9, 2026
54Jane Street Group, LLC14,866New0.03%$0 MNov 12, 2026
55Wells Fargo & Company/mn14,637-22,291 (-60.36%)0.03%$0 MNov 16, 2026
56Stonebridge Capital Advisors LLC14,5000 (0.00%)0.03%$0 MNov 13, 2026
57MetLife Investment Management, LLC13,133-7,247 (-35.56%)0.02%$0 MNov 16, 2026
58Vanguard Global Advisers, LLC12,474+173 (+1.41%)0.02%$0 MNov 13, 2026
59Focus Partners Wealth11,951New0.02%$0 MNov 12, 2026
60Police & Firemen's Retirement System of New Jersey10,1990 (0.00%)0.02%$0 MNov 9, 2026
61BNP Paribas Financial Markets9,272+3,378 (+57.31%)0.02%$0 MNov 12, 2026
62Russell Investments Group, Ltd.9,193+25 (+0.27%)0.02%$0 MNov 6, 2026
63Royal Bank Of Canada8,220-16,102 (-66.20%)0.02%$0 MNov 16, 2026
64Allworth Financial LP8,171+114 (+1.41%)0.02%$0 MNov 17, 2026
65UBS Group AG6,733-16,116 (-70.53%)0.01%$0 MNov 10, 2026
66MassMutual Private Wealth & Trust, FSB4,8240 (0.00%)0.01%$0 MOct 5, 2026
67Farther Finance Advisors, LLC4,703+468 (+11.05%)0.01%$0 MOct 8, 2026
68US Bancorp \de\4,373+38 (+0.88%)0.01%$0 MNov 5, 2026
69Legal & General Group Plc3,7990 (0.00%)0.01%$0 MNov 16, 2026
70Strs Ohio3,200+900 (+39.13%)0.01%$0 MOct 30, 2026
71GK Wealth Management LLC2,810New0.01%$0 MOct 9, 2026
72New York State Common Retirement Fund2,7810 (0.00%)0.01%$0 MNov 17, 2026
73Global Retirement Partners, LLC2,717New0.01%$0 MNov 10, 2026
74Ameritas Investment Partners, Inc.2,6970 (0.00%)0.01%$0 MNov 13, 2026
75Persistent Asset Partners Ltd2,6130 (0.00%)0.00%$0 MNov 13, 2026
76Tower Research Capital LLC (TRC)2,481-1,201 (-32.62%)0.00%$0 MNov 16, 2026
77UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC2,270+2,067 (+1018.23%)0.00%$0 MNov 16, 2026
78Citigroup Inc1,914-15,358 (-88.92%)0.00%$0 MNov 4, 2026
79Steward Partners Investment Advisory, LLC1,5000 (0.00%)0.00%$0 MNov 13, 2026
80Legend Financial Advisors, Inc.1,500New0.00%$0 MNov 16, 2026
81Jones Financial Companies Lllp1,486New0.00%$0 MNov 13, 2026
82Sterling Capital Management LLC1,202+1,073 (+831.78%)0.00%$0 MOct 22, 2026
83TD Waterhouse Canada Inc.1,0700 (0.00%)0.00%$0 MOct 16, 2026
84Capital Analysts, LLC1,0500 (0.00%)0.00%$0 MNov 13, 2026
85Simplex Trading, LLC746New0.00%$0 MNov 4, 2026
86California State Teachers Retirement System4810 (0.00%)0.00%$0 MNov 13, 2026
87GAMMA Investing LLC426+223 (+109.85%)0.00%$0 MOct 8, 2026
88Arax Advisory Partners180+172 (+2150.00%)0.00%$0 MNov 12, 2026
89SJS Investment Consulting Inc.104New0.00%$0 MOct 26, 2026
90SBI Securities Co., Ltd.100New0.00%$0 MOct 22, 2026
91Quarry LP91New0.00%$0 MNov 16, 2026
92EverSource Wealth Advisors, LLC39+34 (+680.00%)0.00%$0 MNov 4, 2026
93Toronto Dominion Bank240 (0.00%)0.00%$0 MNov 16, 2026
94Caitong International Asset Management Co., Ltd18+7 (+63.64%)0.00%$0 MOct 29, 2026
95Root Financial Partners, LLC16New0.00%$0 MOct 21, 2026
96PNC Financial Services Group, Inc.140 (0.00%)0.00%$0 MNov 6, 2026
97Rothschild Investment LLC6New0.00%$0 MNov 10, 2026

Mutual funds holding DiaMedica Therapeutics Inc.#

65 funds hold shares worth $22 M (about 6.0% of the company). Since their previous reports 36 added shares and 10 sold, buying $2 M net.
Mutual funds holding DiaMedica Therapeutics Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors933,319$7 M1.7%<0.01%+12%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC399,641$3 M0.74%<0.01%+18%Jul 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.355,523$3 M0.66%<0.01%+6.6%Jun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors344,134$2 M0.64%0.02%+23%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.176,697$1 M0.33%<0.01%+5.2%May 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC158,705$1 M0.29%<0.01%−2.2%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors123,057$1 M0.23%0.06%+42%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.88,387$1 M0.16%<0.01%+18%Jul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC75,566$1 M0.14%<0.01%+32%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC60,738$0 M0.11%<0.01%no changeMay 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC48,349$0 M0.09%<0.01%+19%Jul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC46,330$0 M0.09%<0.01%+5.5%May 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC36,487$0 M0.07%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC34,197$0 M0.06%0.02%+31%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC33,312$0 M0.06%<0.01%−10%May 31, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.32,141$0 M0.06%0.01%+3.1%May 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation20,900$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.18,987$0 M0.04%<0.01%+7.8%Jun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC17,486$0 M0.03%<0.01%+17%Jul 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.14,610$0 M0.03%<0.01%+86%Jun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC15,861$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.13,097$0 M0.02%0.02%−4.5%Jun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC12,435$0 M0.02%<0.01%+156%Jun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.13,251$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company13,330$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.11,200$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC12,165$0 M0.02%<0.01%+14%Jul 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC9,440$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC9,336$0 M0.02%<0.01%+24%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS8,594$0 M0.02%<0.01%+34%Jun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION9,900$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC8,275$0 M0.02%0.03%+30%Jun 30, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC7,252$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC6,497$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC6,416$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.5,746$0 M0.01%<0.01%+20%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.5,590$0 M0.01%<0.01%+49%Jun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC5,538$0 M0.01%<0.01%+27%Jun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC5,168$0 M<0.01%<0.01%+47%Jun 30, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC5,293$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC4,501$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC4,780$0 M<0.01%<0.01%+3.0%Jul 31, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC3,335$0 M<0.01%0.02%+29%Jun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC3,540$0 M<0.01%<0.01%−0.6%Jul 31, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS3,498$0 M<0.01%<0.01%+60%Jul 31, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC3,140$0 M<0.01%<0.01%+134%Jun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC3,140$0 M<0.01%<0.01%+134%Jun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC3,449$0 M<0.01%<0.01%−2.1%Jul 31, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC2,884$0 M<0.01%<0.01%+33%Jun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC3,161$0 M<0.01%<0.01%+24%Jul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management2,697$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC2,671$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC2,236$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.2,407$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS2,095$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC1,617$0 M<0.01%<0.01%+9.9%May 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC1,336$0 M<0.01%<0.01%−39%Jun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC1,223$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC1,264$0 M<0.01%<0.01%−40%May 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC1,275$0 M<0.01%<0.01%−39%May 31, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC1,005$0 M<0.01%<0.01%+7.8%Jun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.885$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC759$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC648$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC161$0 M<0.01%<0.01%+21%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 65 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at DiaMedica Therapeutics Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$3.4 M
4 purchases, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$3.4 M
open market only
Insiders on file
19
since
$16.8 M$0Nov 2023: bought $49 K (1 trades), sold $0 (0 trades)Nov 23Jun 2024: bought $3.0 M (2 trades), sold $0 (0 trades)JunJul 2025: bought $16.8 M (3 trades), sold $0 (0 trades)JulAug 2025: bought $6.0 M (9 trades), sold $0 (0 trades)AugNov 2025: bought $7.6 M (7 trades), sold $0 (0 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
DiaMedica Therapeutics Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Dietrich John PaulsPresident & CEO, DirectorGrant or award+60,200——128,791Form 4
filed Randall Michael GiuffreDirectorGrant or award+6,175$8.420$52 K398,587Form 4
filed James T. ParsonsDirectorGrant or award+10,095$8.420$85 K97,949Form 4
filed Charles Pauling SembaDirectorGrant or award+3,355$8.420$28 K47,963Form 4
filed Ab Trill10% ownerBuyindirect+73,099$8.570$626 K8.83 MForm 4
filed Ab Trill10% ownerBuyindirect+40,253$7.890$318 K8.75 MForm 4
filed Ab Trill10% ownerBuyindirect+208,872$7.410$1.5 M8.71 MForm 4
filed James T. ParsonsDirectorOption exercise+12,000$2.200$26 K87,854Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: DiaMedica Therapeutics Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
5.0 M
9.3% of shares · 24.77 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2024-12-20 20:50 UTC, code LUDP, resumed 21:00 UTC

Fails to deliver

  • : 1,452 shares at $8.69
  • : 2,445 shares at $8.72
  • : 3,897 shares at $8.69
  • : 519 shares at $7.87
  • : 1,100 shares at $7.57

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

DiaMedica Therapeutics Inc. scorecard#

Passes 1 of the 10 checks that could be worked out. Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median8.4×Price to book 8.4× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-6.2%Free cash flow is -6.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • ✗Net income higher than five years earlier-$33 M-$33 M in fiscal 2025 against -$12 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$33 MNet income -$33 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-67.7%-67.7% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities11.8×Current ratio 11.82 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

DiaMedica Therapeutics Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

DiaMedica Therapeutics Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017
Income statement
Revenue———————0.5—
Research and development2519137.88.88.2r7.94.53.2
General and administrative9.87.68.26.24.94.5r3.72.71.3
Operating expenses342721141413127.34.5
Operating income−34−27−21−14−14−13−12−6.8−4.5
Interest and finance income1.72.32.0——————
Other non-operating income (expense)1.72.31.90.40.10.41.01.10.3
Income before tax−33−24−19−14−14−12−11−5.7−4.3
Income tax0.00.00.00.00.00.00.00.1—
Net income attributable to shareholders−33−24−19−14−14−12−11−5.7−4.3
Earnings per share, basic-0.70-0.60-0.60-0.52-0.65-0.78-0.89-0.74-0.72
Earnings per share, diluted————-0.65-0.78-0.89-0.74-0.72
Shares, weighted average (basic)4740332621————
Shares, weighted average (diluted)————2116127.75.9
Balance sheet
Cash and cash equivalents163.04.54.74.77.43.9171.4
Short-term investments4441482940204.0——
Receivables0.30.20.40.10.10.30.80.80.1
Other current assets0.50.20.40.30.2r0.1r0.00.4—
Current assets6145543445288.8181.5
Property, plant and equipment0.10.10.10.10.10.10.10.10.0
Right-of-use (leased) assets0.20.30.40.40.00.10.2——
Non-current assets0.71.70.50.60.10.20.20.40.3
Total assets6146543446289.1181.8
Accounts payable1.50.90.90.70.51.10.20.50.5
Current liabilities5.15.42.82.21.52.01.31.31.0
Lease liabilities (non-current)0.10.20.30.4r0.0r0.00.1——
Non-current liabilities0.10.20.30.40.00.10.10.0—
Retained earnings−173−140−116−96−83−69−57−46−40
Shareholders' equity5641513244267.6170.8
Total liabilities and equity6146543446289.1181.8
Shares outstanding54433826261912126.4
Cash-flow statement
Share-based compensation3.82.11.71.51.61.81.20.60.4
Cash from operating activities−29−22−19−12−12−9.2−9.1−5.7−3.9
Capital expenditure−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.1−0.0
Cash from investing activities−2.28.6−1812−21−16−3.9−0.1−0.0
Shares issued43123703029—152.9
Cash from financing activities441237−0.030290.1213.5
Change in cash13−1.5−0.20.0−2.73.5−1315−0.4
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at DiaMedica Therapeutics Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.7 M
Rick Pauls
Other top executives, average
$1.5 M
the CEO earned 1.9× this
$100 invested is now
$504
DiaMedica Therapeutics Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Rick Pauls$2.7 M$5.3 M$1.5 M$504
2024Rick Pauls$1.6 M$2.4 M$994 K$344
2023Rick Pauls$1.2 M$1.4 M$587 K$180

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at DiaMedica Therapeutics Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 5 · Material agreement 3 · Unregistered share sale 2 · Shareholder vote 3 · Results announced 11

DiaMedica Therapeutics Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Directors and officers8-K
Material agreementUnregistered share sale8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Directors and officersShareholder vote8-K
Results announced8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of DiaMedica Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2025$30 MPrivate placement after listing$10 to $50 million14equitySEC
Jun 2024$12 MPrivate placement after listing$10 to $50 million10equitySEC
Jun 2023$38 MPrivate placement after listing$10 to $50 million34equitySEC
Sep 2021$30 MPrivate placement after listing$10 to $50 million10equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How DiaMedica Therapeutics Inc. compares in Biotechnology

  • Market cap$469 M · higher than 57% of 726
  • Price / book8.4× · lower than 19% of 534
  • FCF yield-6.2% · higher than 67% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
DiaMedica Therapeutics Inc.🇺🇸$469 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 28, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at DiaMedica Therapeutics Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show DiaMedica Therapeutics Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about DiaMedica Therapeutics Inc.? Suggest a correction